Mixed dyslipidemias in primary care patients in France

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 247-254

  Laforest, Laurent ^a   Ambegaonkar, Baishali M ^b   Souchet, Thierry ^c   Sazonov, Vasilisa ^b   Van Ganse, Eric ^a  

^a UNIVERSITÉ DE LYON   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Dohme Chibret Centre de Recherche Riom   (France)

Author keywords

Cholesterol; Dyslipidemias; France; Prevalence; Treatment outcome; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 TRIGLYCERIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

AGED; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FRANCE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYNDROME DELINEATION; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACOEPIDEMIOLOGY; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RISK; STATISTICS;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; DYSLIPIDEMIAS; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 84865614748     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S27668     Document Type: Article

References (42)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2): 227-239.
2. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28(19):2375-2414.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24(17):1601-1610.
4. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983;52(4):9B-12B.
5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714.
6. Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 1979;109(3):296-308.
7. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol. 1992;70(7):733-737.
8. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102(16):1893-1900.
9. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-1310.
10. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag. 2009;5(1):89-95.
11. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185-197.
12. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dosespecific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract. 2003;4:18.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
14. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48(9):1774-1781.
15. Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta. 2000;1529(1-3):321-330.
16. Benlian P, Etienne J, de Gennes JL, et al. Homozygous deletion of exon 9 causes lipoprotein lipase deficiency: possible intron-Alu recombination. J Lipid Res. 1995;36(2):356-366.
17. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med. 1996;335(12):848-854.
18. Hokanson JE. Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Curr Opin Lipidol. 1999;10(5):393-399.
19. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99(22):2901-2907.
20. Thorn JA, Needham EW, Mattu RK, Stocks J, Galton DJ. The Ser447-Ter mutation of the lipoprotein lipase gene relates to variability of serum lipid and lipoprotein levels in monozygotic twins. J Lipid Res. 1998;39(2):437-441.
21. Gagne SE, Larson MG, Pimstone SN, et al. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin Genet. 1999;55(6):450-454.
22. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol. 2005;59(4):456-463.
23. Ferrieres J, Gousse ET, Fabry C, Hermans MP. Assessment of lipidlowering treatment in France-the CEPHEUS study. Arch Cardiovasc Dis. 2008;101(9):557-563.
24. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005;21(9):1389-1399.
25. Dupuy AM, Carriere I, Scali J, et al. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. Climacteric. 2008;11(1):74-83.
26. Dallongeville J, Bringer J, Bruckert E, et al. Abdominal obesity is associated with ineffective control of cardiovascular risk factors in primary care in France. Diabetes Metab. 2008;34(6 Pt 1):606-611.
27. Kolovou GD, Anagnostopoulou KK, Damaskos DS, et al. Gender differences in the lipid profile of dyslipidemic subjects. Eur J Intern Med. 2009;20(2):145-151.
28. Lozano JV, Pallares V, Cea-Calvo L, et al. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr Med Res Opin. 2008;24(3):659-670.
29. Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther. 2007;29(8):1671-1681.
30. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10(4):S1-S10.
31. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21(12):1927-1934.
32. Agence Française de Sécurité Sanitaire des Produits de Santé. Prise en charge thérapeutique du patient dyslipidémique. Saint-Denis Cedex, France: AFSSPS; 2005. French.
33. Laforest L, Moulin P, Souchet T, et al. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. Atherosclerosis. 2008;199(2):368-377.
34. Van Ganse E, Souchet T, Laforest L, et al. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis. 2006;185(1):58-64.
35. Chassany O, Le-Jeunne P, Duracinsky M, Schwalm MS, Mathieu M. Discrepancies between patient-reported outcomes and clinicianreported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease. Value Health. 2006;9(1): 39-46.
36. Amouyel P, Lamarque H, Gayet JL. Treatment with statins in general medicine: dosage and effectiveness. Results of the observational study STATIMED. Arch Mal Coeur Vaiss. 2005;98(12): 1206-1211. French.
37. Graesslin O, Hoffet M, Barjot P, et al. Preliminary results from the OPNI observatory: long-term follow-up of a cohort of women using the progestagen contraceptive implant Implanon. Gynecol Obstet Fertil. 2005;33(5):315-321. French.
38. Bouee S, Charlemagne A, Fagnani F, et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine. 2004;71(3):214-220.
39. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
40. Putzer G, Roetzheim R, Ramirez AM, Sneed K, Brownlee HJ Jr, Campbell RJ. Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice. J Am Board Fam Pract. 2004;17(2):101-107.
41. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 2005;28(3):595-599.
42. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11(5):306-312.